Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1994-8-4
pubmed:abstractText
In order to describe renal involvement in aggressive non-Hodgkin's lymphomas (NHLs) and its prognostic significance, we reviewed the outcome of 48 patients with renal involvement treated with the LNH-84 or LNH-87 regimen. Histology was diffuse large cell in 29 (60%) patients; immunoblastic, diffuse mixed cell and lymphoblastic in four each; follicular large cell, diffuse small cleaved cell and diffuse small non-cleaved cell in one each; and unclassified in four. Ann Arbor stage was IV in 44 patients, and IE or IIE in four. Tumour mass > or = 10 cm, performance status (ECOG scale) > 2 and increased LDH level were present in 69%, 20% and 76% of patients respectively. Fifteen patients (31%) had multiple intraparenchymal nodules, 14 (29%) had direct spread into the kidney from a perirenal mass, ten (21%) had a single intraparenchymal nodule and nine (19%) had diffuse infiltration. Twenty-one patients (43%) presented with bilateral lesions. Three patients (6%) presented with acute renal failure. Ten other patients (21%) had serum creatinine > 120 mumol l-1. In 12 of these 13 patients renal function was restored with chemotherapy. Twenty-eight patients (57%) achieved complete remission. Estimated 4 year disease-free survival was 39%. Disease-free survival and actuarial survival at 4 years were estimated to be 58% respectively. Two renal parameters had adverse prognostic significance for survival: renal hilum involvement (P = 0.02) and diffuse renal infiltration (P = 0.01). A Cox model identified only two independent prognostic factors for survival, namely performance status > or = 2 and tumour size > or = 10 cm. We conclude that alteration in renal function occurs in 27% of patients with renal involvement. Systemic chemotherapy improves renal function rapidly. Long-term outcome is similar to that expected in NHL patients presenting with the same prognostic factors.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-13252687, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-14492019, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-1703226, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-2344997, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-2474057, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-3052998, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-3061580, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-3383463, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-3524795, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-3594375, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-3780803, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-3953939, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-3998781, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-4900435, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-5121694, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-5326510, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-5910392, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-6185193, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-6687600, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-6883276, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-6979211, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-7111721, http://linkedlifedata.com/resource/pubmed/commentcorrection/7517172-793711
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
70
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
154-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:7517172-Humans, pubmed-meshheading:7517172-Adolescent, pubmed-meshheading:7517172-Kidney, pubmed-meshheading:7517172-Aged, pubmed-meshheading:7517172-Creatinine, pubmed-meshheading:7517172-Kidney Neoplasms, pubmed-meshheading:7517172-Prognosis, pubmed-meshheading:7517172-Female, pubmed-meshheading:7517172-Male, pubmed-meshheading:7517172-Lymphoma, Non-Hodgkin, pubmed-meshheading:7517172-Treatment Outcome, pubmed-meshheading:7517172-Adult, pubmed-meshheading:7517172-Lymphoma, Large B-Cell, Diffuse, pubmed-meshheading:7517172-Prednisolone, pubmed-meshheading:7517172-Lymphoma, Follicular, pubmed-meshheading:7517172-Middle Aged, pubmed-meshheading:7517172-Methotrexate, pubmed-meshheading:7517172-Methylprednisolone, pubmed-meshheading:7517172-L-Lactate Dehydrogenase, pubmed-meshheading:7517172-Cyclophosphamide, pubmed-meshheading:7517172-Antibiotics, Antineoplastic, pubmed-meshheading:7517172-Survival Rate, pubmed-meshheading:7517172-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:7517172-Remission Induction, pubmed-meshheading:7517172-Neoplasm Staging, pubmed-meshheading:7517172-Chi-Square Distribution, pubmed-meshheading:7517172-Survival Analysis, pubmed-meshheading:7517172-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:7517172-Bleomycin, pubmed-meshheading:7517172-Doxorubicin, pubmed-meshheading:7517172-Actuarial Analysis, pubmed-meshheading:7517172-Vindesine, pubmed-meshheading:7517172-Lymphoma, Large-Cell, Immunoblastic, pubmed-meshheading:7517172-Proportional Hazards Models
More...